Logo

Your free order overview

You currently have not items to display
Logo

Your contact details

This is a required field

Logo

Thank you!

Thank you for choosing Janssen Medical Cloud for ordering your materials.

/
SCHÉMA DE L’ÉTUDE(1,2)

SCHÉMA DE L’ÉTUDE(1,2)

schema-de
imbruvica-graph
schema-de-2

CRITÈRES D’ANALYSE(1,2)

  • Taux de réponse
  • Durée de la réponse
  • Survie sans progression (PFS)
  • Survie Globale (OS)
  • Tolérance

References:

  1. Ysebaert L et al. Real-world results of ibrutinib in relapsed/refractory CLL in France : early results on a large series of 428 patients. Am J Hematol 2017 Apr 25. doi:10.1002/ajh.24773. Epub 2017 May 30.
  2. Michallet AS et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia : a real-world experience of 71 patients treated in France : a study from the French Innovative Leukemia Organization (FILO) group . Am J Hematol. 2017 Jun ; 92(6) : E105-E107. doi:10.1002/ajh.24715. Epub 2017 Apr 29.

CP-214345

Logo
This site is published by ©Johnson & Johnson Innovative Medicine NV which is solely responsible for its content. It is intended for European, Middle Eastern and African Healthcare professionals.
Johnson & Johnson Pharmaceutica NV
Legal NoticePolitique de confidentialitéMentions légalesPolitique in matiere de cookies
Cookie Settings